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Topical Application of Sphingosine-1-Phosphate and
FTY720 Attenuate Allergic Contact Dermatitis
Reaction through Inhibition of Dendritic Cell
Migration
Ilka Reines1, Manfred Kietzmann1, Reinhard Mischke2, Thomas Tschernig3, Anja Lu¨th4, Burkhard Kleuser4
and Wolfgang Ba¨umer1
Migration of Langerhans cells (LCs) from the skin to the lymph node is an essential step in the pathogenesis of
allergic contact dermatitis (ACD). Therefore, inhibition of LC-migration could be a promising strategy to
improve this skin disease. Effects of sphingosine-1-phosphate (S1P) and the immunomodulator FTY720 on LC
trafficking is not well defined, yet. Thus, we investigated the action of topically administered S1P and FTY720 in a
murine model of ACD. Most interestingly, FTY720 as well as S1P inhibited the inflammatory reaction in the
elicitation phase of ACD. In the sensitization phase, FTY720, and S1P reduced the weight and cell count of the
draining auricular lymph node, as well as immigrated dendritic cells provoked by repetitive topical
administration of the hapten. Correspondingly, the density of LCs in the epidermis was higher in FTY720-
and S1P-treated mice compared to vehicle treatment. A skin dendritic cell migration assay confirmed the
significant inhibition of dendritic cell migration by FTY720 and S1P. These data supply conclusive evidence that
the strategy of targeting the migratory response of LCs with locally acting S1P or FTY720 represents an emerging
option in the treatment of allergic skin diseases like contact hypersensitivity and atopic dermatitis.
Journal of Investigative Dermatology (2009) 129, 1954–1962; doi:10.1038/jid.2008.454; published online 5 February 2009
INTRODUCTION
Sphingosine-1-phosphate (S1P) has been shown to act as a
critical signaling molecule and to elicit a variety of partially
contrasting cellular effects. The significance of S1P in
immune cell regulation became obvious when it was
discovered that the immunosuppressive drug FTY720 (Fingo-
limod) causes lymphopenia through S1P signaling (Mandala
et al., 2002). S1P is part of the lipid fraction securing the
epidermal permeability barrier. Sphingosine can be cleaved
from ceramides, which account for 30–40% of stratum
corneum lipids (Herzinger et al., 2007). Sphingosine can then
be phosphorylated by sphingosine kinases to S1P, which binds
to a family of G-protein-coupled receptors, named S1P1–S1P5.
S1P signaling is inactivated irreversibly by a S1P lyase.
FTY720 is a synthetic structural analog of mytiocin, a
metabolite of Isaria cinclarii. The efficacy of FTY720 has been
well established in preclinical transplantation models and
also in renal transplantation in humans (Tedesco-Silva et al.,
2005). However, in contrast to classical immunosuppressant
drugs, FTY720 does not interfere with T-cell proliferation or
apoptosis, but induces a severe deprivation in lymphocytes in
the blood due to modification of S1P signaling. FTY720
shares structural characteristics with sphingosine and is also a
substrate for the sphingosine kinase. Once phosphorylated,
FTY720-P acts as an agonist on four of the five known S1P
receptors (S1P1, S1P3, S1P4, and S1P5). However, in contrast
to the physiological ligand S1P, FTY720-P is not a substrate of
the S1P lyase and is therefore only metabolized by
phosphatases (von Wenckstern et al., 2006). This discrepancy
is a crucial factor in the altered behavior of FTY720-P toward
S1P receptors resulting in a distinct immune modulation by
FTY720-P compared with S1P.
SEW2871, another S1P receptor (S1PR) agonist with a low
EC50 on the human S1P1 (B13 nmol l
1) and virtually no
action on other S1P receptors induces a transient internaliza-
tion of S1P1 after systemic administration comparable to the
See related commentary on pg 1852ORIGINAL ARTICLE
1954 Journal of Investigative Dermatology (2009), Volume 129 & 2009 The Society for Investigative Dermatology
Received 6 August 2008; revised 3 December 2008; accepted 10 December
2008; published online 5 February 2009
1Department of Pharmacology, Toxicology, and Pharmacy, University of
Veterinary Medicine Hannover, Hannover, Germany; 2Small Animal Clinic,
University of Veterinary Medicine Hannover, Hannover, Germany;
3Department of Functional and Applied Anatomy, Medical School of
Hannover, Hannover, Germany and 4Institute of Pharmacy, Pharmacology
and Toxicology, Free University Berlin, Berlin, Germany
Correspondence: Prof. Dr. Wolfgang Ba¨umer, Institute of Pharmacology,
Toxicology, and Pharmacy, University of Veterinary Medicine Hannover,
Hannover, 30559, Germany.
E-mail: wolfgang.baeumer@tiho-hannover.de
Abbreviations: DC, dendritic cell; LC, Langerhans cell; S1P, sphingosine-1-
phosphate; S1PR, sphingosine-1-phosphate receptor; TDI, toluene-2,4-
diisocyanate
natural ligand S1P (Sanna et al., 2004, Gollmann et al.,
2008). Mice treated orally with SEW2871 developed acute
lymphopenia, which was reversed, when SEW2871 levels in
the plasma declined (Sanna et al., 2004). However, a
transient increase of blood DC in mice was also noticed
(Lan et al., 2005).
It is well described that some central dendritic cell
functions (migration, cytokine secretion) can also be modu-
lated in vitro by S1P and FTY720 (Renkl et al., 2004; Muller
et al., 2005). Dendritic cells play a pivotal role in the
initiation and elicitation of allergic diseases. Langerhans cells
as well as dermal dendritic cells (DCs), carry haptens (like
toluene-2,4-diisocyanate) from the skin through afferent
lymphatic vessels to draining lymph nodes, where these
haptens, bound to peptides, are presented to T cells, which
then become specific T cells (induction phase). When the
hapten is painted for a second time, it diffuses through the
skin and could be loaded onto Langerhans cells or dermal
dendritic cells, which in turn present the hapten to specific
T cells. These specific T cells are then activated and respond
with cytokine production and activation of further inflamma-
tory cells (elicitation phase; reviewed in: (Krasteva et al.,
1999; Kimber et al., 2002)).
It has been demonstrated that the mRNA for the S1P1,
S1P2, S1P3, and S1P4 is expressed on the murine Langerhans
cell line XS 52. These data are corroborated by a study on
immature and mature murine bone marrow DCs. The mRNA
for S1P2, S1P3, and S1P4 have been found on both immature
and mature DCs, whereas S1P1 was only found on mature
DCs (Czeloth et al., 2005). However, it was shown that only
S1P1 and S1P3 receptors are involved in cell migration
towards S1P (Czeloth et al., 2005; Radeke et al., 2005).
This study was performed to examine effects of topically
administered S1P, FTY720, and SEW2871 on dendritic cell
migration in the induction phase as well as the inflammatory
response in the elicitation phase in a model of toluene-2,4-
diisocyanate (TDI) induced allergic contact dermatitis.
RESULTS
Local lymph node test in the sensitization phase
A repetitive sensitization with 0.5% TDI induced no
remarkable ear swelling, indicating that the selected dose is
not irritating (vehicleþ TDI treated ears: 2 (±14) mm,
S1Pþ TDI treated ears 3 (±5) mm).
The topical administration of TDI induced a significant
increase in local lymph node weight and cell count. This
increase is abolished by topical administration of S1P (Figure
1a). A similar effect was observed by topical administration of
FTY720, indicating a reduced T-cell stimulation. The S1P1
agonist SEW2871 had no significant impact on lymph node
weight or cell count (Figure 1b).
Dendritic cells in lymph nodes and in vitro stimulation
The amount of CD11c/CD40þ cells (that is, dendritic cells
from skin) in local lymph nodes also increased after TDI
sensitization. The amount of skin dendritic cells is reduced to
basal levels by topical administration of S1P (Figure 2a).
Topical administration of FTY720 also led to a significant
decrease in CD11c/CD40þ cells in the draining lymph node,
whereas SEW2871 had only a minor impact on immigrated
DCs (Figure 2b).
Lymph node cells from TDI-sensitized mice stimulated
with Con A respond with an increased secretion of IL-6 and
IFNg. This secretion is significantly lower in lymph node cells
from S1P- and FTY720-treated animals (Table 1). SEW2871
did not reduce the Con A-induced IL-6 (data not shown)
secretion. As SEW2871 also had no impact upon ear swelling
in the challenge reaction (not shown), SEW2871 was omitted
for subsequent experiments.
Impact of S1P1 and S1P3 on dendritic cell migration
SEW2871 had a lower effect on dendritic cell migration
through skin compared with S1P and FTY720. SEW2871
acts solely through S1P1. But as it was demonstrated in
antisense oligonucleotide experiments that S1P3 is also
involved in DC migration toward S1P (Radeke et al.,
2005), it was tested whether a dual S1P1/S1P3 (VPC23019)
antagonist displays superior inhibitory effect on DC
migration compared with solely S1P1 (W146) inhibition.
Both inhibitors reduced the DC migration towards S1P.
However, the dual inhibitor VPC23019 reduced migration to
basal control levels and thus showed a significantly higher
inhibition of migration compared with the S1P1 antagonist
W146 (Figure 2c).
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Figure 1. Lymph node weight (mg, gray bars) and cell count ( 106 cells, open bars) from the draining lymph nodes of mice 24 h after the third sensitization
with TDI. Mice received S1P (100 mg, a) or FTY720 (10 mg) and SEW2871 (b), or vehicle (methanol) over 9 days. From day 7 on, mice received TDI (0.5%)
onto the inner and outer surface of the ears. Twenty-four hours after the third sensitization with TDI, mice were killed and the local lymph node was weighed
and cells were counted in the lymph node suspension. Untreated controls served as basal values, n¼ 6 each group, **Po0.01 compared to vehicle.
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MHC class II positive cells in the epidermis
Compared to vehicle, the treatment with S1P resulted in a
significant higher cell count of major histocompatibility
complex (MHC) class IIþ cells (that is, Langerhans cells) in
the epidermis of TDI-sensitized mice 24 hours after last
sensitization (Figure 3a). Topical administration of FTY720
resulted in a similar effect (Figure 3b).
Skin dendritic cell migration assay
Twenty-four hours after last sensitization, the cartilage-free
ear halves were cultivated with TDI for 3 days further to
determine skin DC migration (Ortner et al., 1996). DC
migration was reduced by topical administration of S1P and
FTY720, corresponding to the higher density of Langerhans
cells observed in epidermal sheets treated with S1P and
FTY720 (Figure 4).
Plasma S1P levels after topical administration
To evaluate a possible systemic effect, mice treated for
9 days with S1P were tested for any elevation in S1P
levels in plasma. After the last S1P treatment and TDI
challenge, mice were killed and S1P levels were detected in
plasma. There was a slight, but significant difference
in plasma concentration of S1P between vehicle-treated and
S1P-treated mice (vehicle-treated mice: 70 (þ6) pmol/ml,
S1P-treated mice: 102 (þ36) pmol/ml).
Lymphocytes in peripheral blood after topical administration of
S1P, FTY720, and SEW2871
Although S1P was only slightly elevated in plasma, topical
administration of S1P, FTY720, and SEW2871 reduced the
number of white blood cells, particularly in lymphocytes
(Figure 5).
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Figure 2. Total number of CD11c/CD40-positive cells (that is, dendritic cells emigrated from skin) in the draining lymph node after third sensitization with
TDI.Mice received S1P (100 mg, a) or FTY720 (10 mg) and SEW2871 (b), or vehicle (methanol) over 9 days. From day 7 onwards, mice received TDI (0.5%) onto
the inner and outer surface of the ears. Twenty-four hours after the third sensitization with TDI, mice were killed and the local lymph node cells were stained
with anti-CD40 and CD11c and the amount of CD11chighCD40high cells were determined by means of flow cytometry, n¼6 each group, **Po0.01, (c):
Migration of BM-derived DCs towards S1P. Effects of a S1P1 (W146) antagonist and a dual S1P1/S1P3 (VPC23019) antagonist on DCs migration towards S1P.
One of two independent experiments (n¼ 4 each group) with similar results, *Po0.05,***Po0.001.
Table 1. Local administration of FTY720 and S1P
modulates cytokine pattern in draining lymph nodes
IL-6 (pgml1) IFNc (pgml1)
Control 3 (±2)** 181 (±10)*
Vehicle 182 (±108) 978 (±593)
S1P 54 (±37)** 237 (±164)*
Control 4 (±2)** 62 (±17)**
Vehicle 327 (±104) 2271 (±743)
FTY720 52 (±3)** 844 (±227)**
Draining lymph node cells from mice were cultivated 24 h after third
sensitization with TDI. Lymph node cells were stimulated in vitro with
Con A for 48 h. IL-6 and IFNg were measured in the supernatants by
ELISA, Mean (±SD) of n=6 for each group, experiment was performed
two times with comparable results, *Po0.05, **Po0.01 compared to
vehicle.
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Impact of topically administered S1P and FTY720 on ear
swelling and T-cell influx in the elicitation phase of allergic
contact dermatitis
When administered before elicitation with TDI, S1P (100 mg
per ear over 9 days) induced a significant inhibition of the ear
swelling measured 24 hours after challenge (Figure 6a).
Comparable reduction of the inflammatory response was
also observed after topical administration of FTY720 (B) for 9
days. Immunohistological evaluation reveals a reduction of
CD3þ cells in FTY720 and S1P-treated mouse ears (Figures 7
and 8). The staining intensity for MHC IIþ cells is also
reduced in the dermis of S1P- and FTY720-treated ears.
However, GR-1þ cells (neutrophil granulocytes) are not
reduced by treatment with S1PR agonists (Figure 7).
DISCUSSION
The results of this study reveal several crucial aspects: first,
topical administration of S1P as well as FTY720 impairs
Langerhans cell (LC) migration through the skin. Second, the
impaired LC-migration is accompanied by a diminished local
lymph node reaction in the sensitization phase and a
diminished inflammatory reaction in the elicitation phase of
allergic contact dermatitis.
Dendritic cells (DCs) are pivotal to both the initiation and
maintenance phase of allergic inflammatory diseases like
atopic dermatitis and allergic contact dermatitis. Thus, it can
be postulated that an inhibition of DC (particularly LC)
migration and activation can at least partly explain an
inhibitory action of immunomodulatory substances. This
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Figure 3. MHC class IIþ cells in the ear epidermis of mice 24 h after last sensitization with TDI. Mouse ears were treated with S1P (a), FTY720 (b) or vehicle
for 9 days. From day 7 to 9, ears were treated topically with TDI (0.5%). Epidermis was stained for MHC class IIþ cells and density was determined
microscopically by means of a calibrated grid, n¼ 4–6 per group, **Po0.01.
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Figure 4. Migration of skin dendritic cells out of mouse ear explants.
Cartilage-free dorsal ear halves were cultivated 24 hours after the third
sensitization with TDI for 3 additional days. Explants were transferred daily
into new wells. Emigrated cells were pooled for each explant, counted with a
hemocytomer and related to the tissue weight. n¼ 6 each group, *Po0.05,
**Po0.01.
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Figure 5. White blood cells (gray bars) and lymphocytes (white bars) of mice
treated topically with S1P, FTY720, and SEW2871 or vehicle. Blood cells
were counted in heparinized blood collected 24 hours after the third
sensitization with TDI. n¼ 4–6 per group, *Po0.05, **Po0.01.
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Figure 6. Ear swelling 24 hours after TDI challenge. Mice were sensitized
and challenged with TDI as described in Materials and Methods. S1P (a) or
FTY720 (b), or vehicle was topically administered for 9 days. On day 9, mice
were challenged with TDI. Ear thickness was measured directly before
challenge and 24 hours after challenge and ear swelling was calculated, n¼ 6
each group, **Po0.01.
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has already been demonstrated for immunomodulators like
cyclosporine A, tacrolimus, rapamycin, cilomilast, and
glucocorticoids (Homey et al., 1998; Panhans-Gross et al.,
2001; Chen et al., 2004; Hoetzenecker et al., 2004; Baumer
et al., 2005, 2006).
In this study, the anti-inflammatory and immunomodula-
tory action of locally administered FTY720 and its natural
ligand S1P was compared. It was presumed that a high
topical administration of sphingosine receptor agonists results
in a receptor internalization (mainly S1P1) and an unrespon-
siveness of skin dendritic cells (Graler and Goetzl, 2004;
Matloubian et al., 2004). The results obtained with the S1P
agonist SEW2871 indicate, that not all effects are mediated
solely through the S1P1, or more precisely its internalization.
In vitro experiments with the S1P1 antagonist W146 and the
S1P1/S1P3 antagonist VPC23019 indicate that blocking of
S1P3 is essential for a complete inhibition of DC migration.
Our results are supported by the recently published study of
Gollmann et al. (2008). Intradermal injection of SEW2871
(B20 mg per mouse ear) reduced the migration of DCs to the
draining lymph node (even under inflammatory conditions).
However, the reduction is not complete. A maximum of
approximately 75% inhibition is achieved by intradermal
injection of SEW2871 (Gollmann et al., 2008). In addition, an
incomplete inhibitory action of SEW2871 can be explained
pharmacokinetically, for example, by a low skin penetration
of SEW2871.
Most studies concerning the action of FTY720 were
carried out by means of a systemic administration of the
S1PR agonist, which results in an inhibition of lymphocyte
egress from the lymph nodes and consequently in peripheral
lymphopenia (Mandala et al., 2002). For instance, a systemic
administration of FTY720 has been demonstrated to prevent
spontaneous dermatitis in NC/Nga mice, which are used as a
mouse model of atopic dermatitis (Kohno et al., 2004). Very
recently it was shown that systemic administration of FTY720
impaired the initiation but not the elicitation phase of allergic
contact dermatitis induced by dinitrofluorobenzene (Naka-
shima et al., 2008). The authors could not find a modulation
of skin dendritic cell migration by systemic administration of
FTY720. Thus, they conclude that systemically administered
FTY720 impairs mainly naive T-cell circulation, which affects
the initiation of allergic contact dermatitis. The purpose of
this study was to examine effects of topically administered
S1PR agonists to reduce possible side effects induced by
peripheral lymphopenia. However, long-term treatment with
S1P and especially FTY720 also resulted in lymphopenia
(Figure 5). Nevertheless, it was intended to study the
modulation of dendritic cell function in the skin. Therefore,
the substances were administered topically.
Analysis of epidermal sheets demonstrate that, compared
with vehicle-treated mouse ears, topical treatment with
FTY720 and S1P leads to an inhibition of Langerhans cell
migration. This is confirmed by the skin dendritic cell
migration assay. The inhibitory effect of FTY720 on skin DC
migration has been demonstrated in non-inflamed skin by
Czeloth et al. (2005) following FITC skin painting after 4 days
of systemic administration of FTY720 (Czeloth et al., 2005).
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Figure 7. Immunhistological staining of CD3þ cells. (a), MHC IIþ cells (b) and GR-1þ cells (c) in the epidermis of TDI-challenged mice. Mice were
sensitized and challenged with TDI as described in Materials and Methods. S1P, FTY720, or vehicle was topically administered for 9 days. On day 9, mice were
challenged with TDI. Ears were stained with anti CD3, anti MHC II and anti-GR-1 antibodies and the staining intensity was evaluated by two persons from 0
(no staining)—3 (strong staining intensity). Mean intensity of each mouse ear is presented, n¼ 6 each group.
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It can be concluded that topically administered FTY720 is
phosphorylated to FTY720P, which represents the active
compound (von Wenckstern et al., 2006).
Comparable to our results, a recent study investigating the
lung demonstrated that relatively high concentrations of
topically administered FTY720 and S1P can reduce DC
migration in lungs accompanied by a reduced allergic
inflammatory response (Idzko et al., 2006). However, it is
noticeable that DC migration towards other chemokines like
CCL19, CCL21 is not affected (Czeloth et al., 2005; Idzko
et al., 2006).
In any case, the reduced allergic inflammatory response
should not solely be explained by a reduced DC migration
but also for example, by a defective T-cell stimulatory effect.
For example, the IL-12 secretion of lung DCs was impaired by
FTY720 treatment (Idzko et al., 2006), which corresponds to
in vitro findings for S1P and FTY720 with human monocyte-
derived DCs (Idzko et al., 2002; Muller et al., 2005). Our
own results show a diminished secretion of IFNg and IL-6 in
Con A-stimulated cells from draining lymph nodes of TDI-
sensitized mice after in vivo treatment with S1P and FTY720,
which also indicates a modulation of the cytokine pattern.
This is corroborated by in vitro findings: a diminished IFNg
secretion has been demonstrated in vitro, when FTY720-
treated DCs were added to allogeneic T cells (Muller et al.,
2005).
In addition, direct effects of S1PR agonists on keratinocyte
function are published. Although most publications indicate
an influence of S1P on keratinocyte proliferation (Kim et al.,
2004; Schuppel et al., 2008), it was also recently shown that
topically administered S1P reduced the epidermal hyperpla-
sia provoked by repeated tape stripping in mice (Hong et al.,
2008). Repeated tape stripping is accompanied by a secretion
of several pro-inflammatory cytokines and chemokines like
TNFa, IL-1b, IL-6, IL-8, and histamine (Wood et al., 1992;
Amano et al., 2007). Thus, topical administration of S1P
might have also an impact on cytokine secretion from
keratinocytes. Own preliminary results indicate, that S1P
(10 mmol l1) reduces the LPS-induced KC secretion (murine
IL-8 homolog) in the murine keratinocyte cell line MSC (data
not shown).
Although it was intended to exclude systemic effects of the
immunomodulators by topical administration, the observed
lymphopenia (Figure 5) and slightly enhanced S1P plasma
levels point towards a systemic effect, which can also
contribute to the anti-inflammatory action observed in the
challenge phase (Figure 6). Interestingly, the accumulation of
T cells is vastly reduced in the elicitation phase by topical
administration of S1PR agonists (Figures 7 and 8). Further-
more, a reduction of MHC IIþ cells is apparent, indicating a
reduced influx of antigen-presenting cells into the site of
antigen challenge. Most striking, this is a cell-specific effect,
as neutrophil influx is not affected by topical-administered
S1PR agonists (Figure 7).
With regard to allergic diseases like atopic dermatitis
it can be postulated that topical administration of FTY720
and S1P may have a benefit and might be superior to
systemic administration of S1PR agonists (Nakashima et al.,
2008). This is supported by the fact that an enhanced
S1P lyase activity has been found in mRNA of lesional
skin from atopic dermatitis patients (Seo et al., 2006).
Thus, it can be speculated that topical S1P has
local immunosuppressive activity in the epidermis and
that reduced S1P levels by an enhanced S1P lyase
activity in skin might be involved in Langerhans cell
activation.
Figure 8. Immunohistological staining of CD3þ cells. Mice were sensitized and challenged with TDI as described in Materials and Methods. Vehicle
(b), FTY720 (c) or S1P (d) was topically administered for 9 days. On day 9, mice were challenged with TDI. Ears were stained with anti-CD3 as described
in Materials and methods. Untreated mouse ears served as basal controls (a), n¼ 6 each group, bars represent 100mm.
www.jidonline.org 1959
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Altogether, the presented data consolidates the strategy of
targeting the migratory response of LCs with locally acting
S1P or FTY720, hence representing a new option in the
treatment of allergic skin diseases like contact hypersensitiv-
ity and atopic dermatitis.
MATERIALS AND METHODS
Reagents
Sphingosine-1-phosphate was purchased from York Pharma (Hom-
berg/Ohm, Germany), SEW2871 and FTY720 were purchased from
Biozol (Eching, Germany). Toluene-2,4,-diisocyanate, lipopolysac-
charide (LPS; O127:B8), and concanavalin A (Con A) were obtained
from Sigma (Deisenhofen, Germany), ammonium thiocyanate from
Riedel de Hae¨n (Hannover, Germany). The S1P1 antagonist W146
and the S1P1/S1P3 antagonist VPC23019 were purchased from Avanti
Polar Lipids (Alabastar, AL). Anti-mouse CD 11c (hamster IgG1, PE-
conjugated, HL3), CD40 (rat IgG2a, FITC-conjugated, 3/23), MHC II (I-
A/I-E, rat IgG2b), and the corresponding isotype controls were ordered
from Pharmingen (Hamburg, Germany). Biotinylated rabbit anti-rat
IgG was from DAKO (Hamburg, Germany), carbocyanin 3 from
Jackson Immunoresearch Laboratories (PA). For immunhistochemis-
try, anti-GR-1, -CD3, -MHC II all came from Dianova (Hamburg,
Germany), bridging antibodies (rat anti-mouse IgG, Z494) and the
APAAP complex (D 488) were obtained from Dako (Hamburg,
Germany). Fast Blue was ordered from Sigma. ELISAs for IL-6 and
IFNg were from R&D systems (Wiesbaden, Germany).
Mice
Female BALB/c-mice with an age of 8 weeks (20 g body weight),
were obtained from Charles River (Sulzfeld, Germany). The mice
were housed in groups of six mice per cage at 221C with a 12-hours
light–dark cycle. Water and a standard diet (Altromin, Lage/Lippe,
Germany) were available ad libitum. All animal procedures were
conducted under experimental license approved by the Bezirksre-
gierung Hannover, Germany (Az. 509.6-42502-03/711).
Induction of sensitization and elicitation in mice
To determine effects of S1P on the sensitization phase, a modified
local lymph node assay was performed (Ehling et al., 2005). Over a
period of 9 days, mouse ears were treated with 100 mg S1P dissolved
in 80 ml methanol. Another group of mice received FTY720 (10 mg in
80 ml) for 9 days. A third group received SEW2870 (100mg in 80 ml
methanol) for 9 days. The dosage for SEW2871 was selected because
of the low EC50 (13 nmmol l
1) on the S1P1 and the quite long
elimination half-life after systemic administration (B7hours; Sanna
et al. 2004). From day 7 vehicle or S1PR agonist-treated ears were
sensitized by application of 20 ml 0.5 % toluene-2,4-diisocyanate
(TDI) in acetone onto the mouse ears. On day 10 ear thickness was
measured, the mice were killed and the Lnn. auriculares were
prepared. The lymph nodes were weighed and cell count was
determined using a hemocytometer (Neubauer, VWR, Darmstadt,
Germany).
TDI-induced allergic dermatitis was performed as described
earlier (Baumer et al., 2004, 2005). After settling in for 1 week, the
abdominal skin of the mice was shaved and depilated with Veet. The
abdominal skin was stripped 10 times with adhesive tapes. For active
sensitization, 50 ml 5% TDI in acetone was administered to the
stripped epidermis on 4 consecutive days. The allergic reaction was
boosted 21 days later by administration of 50 ml 0.5 % TDI in
acetone onto the shaved abdomen. Starting on day 19, mouse ears
were treated with 100 mg S1P or 100mg SEW2871 in 80ml methanol
for 9 days. Another group of mice received FTY720 (10 mg in 80 ml)
for 9 days. The allergic reaction was challenged by administration of
20 ml 0.5 % TDI in acetone onto the mouse ears treated with vehicle
or S1PR agonists. The swelling was calculated by a comparison of
the ear thickness (cutimeter, Mitutoyo, Neuss, Germany) before and
24 hours after challenge.
Determination of S1P in blood plasma and determination of
lymphocytes in blood
Twenty-four hours after TDI challenge, mice were killed, and blood
was taken from vehicle-treated and S1PR agonist-treated animals.
Blood was collected in siliconized vials coated with heparine. The
vials were centrifuged and S1P levels in the plasma were measured
using a method recently described by Ruwisch et al. (2001). In brief,
plasma was diluted in phosphate-buffered saline and mixed with
methanol/hydrochloric acid (HCl). As internal standard dihydro-S1P
was supplemented. Lipids were extracted by addition of chloroform
and 4M NaCl. For alkalization, 3 N NaOH were added. The organic
phase was re-extracted from the aqueous phase with methanol, 1M
NaCl and 3 N NaOH. The aqueous phases were combined, acidified
and extracted two times with chloroform. The organic phases were
evaporated, and the dried lipids dissolved in 275 ml methanol/0.07M
K2HPO4 (9:1). A derivatization mixture of o-phthaldialdehyde,
ethanol, 2-mercaptoethanol, and 3% boric acid was prepared and
adjusted to potassium hydroxide (pH) 10.5 with KOH. Then, 25 ml of
the derivatization mixture was added to the resolved lipids. The
derivatives were analyzed by a Merck Hitachi LaChrom 842 HPLC
system (Merck Hitachi, Darmstadt, Germany) using a RP18 Kromasil
column (Chromatographie Service, Langerwehe, Germany). Separa-
tion was carried out using a gradient of methanol and 0.07M
K2HPO4. Resulting profiles were evaluated using the Merck system
manager software. The recovery of S1P was calculated using
dihydro-S1P as standard.
Twenty-four hours after the third sensitization (18 hours after last
S1PR agonist treatment), blood was collected in heparine-coated
vials and white blood cells and lymphocytes were determined using
a flow-cytometry-based automated hematology system with a
veterinary software package designed for different species including
the mouse (Advia 120, Siemens Medical Solutions Diagnostics,
Eschborn, Germany).
Skin dendritic cell migration assay
Twenty-four hours after challenge and determination of ear swelling,
the mice were killed by cervical dislocation. The cartilage-free
dorsal halves of split mouse ear skin were cultured in 24-well size
plates based on a method of Ortner et al. (1996). The halves were
placed onto tables made of sieves with the epidermal side facing
upwards. The tables were transferred daily to new wells with fresh
media. Migrated cells from each ear were pooled and counted with a
hemocytometer (Neubauer, VWR, Darmstadt, Germany). The
viability of the cells was assessed by trypan blue exclusion.
Chemotaxis assay for bone marrow-derived DCs
Bone marrow-derived murine DCs were cultivated with murine GM-
CSF according to a standard protocol (Lutz et al., 1999). The
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chemotaxis assay was performed in a trans well system as described
elsewhere (Renkl et al., 2004). There exists a discrepancy in the
literature, whether immature DCs respond to the same extent to S1P
as mature DCs (Renkl et al., 2004, Czeloth et al., 2005). We
therefore stimulated half of the DCs with LPS (500 ngml1) and
performed the chemotaxis assay with a 1:1 ratio of immature and
mature DCs. A part of the DCs was pre-incubated with 1mmol l1
W146 and VPC23019, respectively. The concentration was selected,
as both antagonists have Ki values in a low nanomolar range at the
S1P1 (Davis et al., 2005, Sanna et al., 2006). Thus, if the antagonists
are administered in excess for blocking S1P1 (1mmol l
1), an
additional effect by VPC23019 is due to the additional S1P3
inhibition. Chemotaxis was induced by 1mmol l1 S1P (Renkl
et al., 2004). Migrated cells were determined 90minutes after
incubation.
Determination of dendritic cells in lymph nodes and in vitro
stimulation
The auricular lymph nodes were prepared and single-cell suspen-
sions were prepared in phosphate-buffered saline. As it has been
reported that DCs in draining lymph nodes, which have migrated
from skin are characterized by both CD11chigh and CD40high (Ohl
et al., 2004), LN cells were stained for CD11c and CD40 or
corresponding isotype controls as described earlier (Baumer et al.,
2006). The percentage of CD11c and CD40 double-positive cells
was determined by flow cytometry (Coulter Epics XL, Beckmann,
Krefeld, Germany with Expo 32 ADC Analysis).
For in vitro stimulation, 5 105 cells from each lymph node were
cultured in RPMI and stimulated with 2mgml1 Con A. Forty-eight
hours after stimulation, supernatant was harvested and kept at
201C until determination of IL-6 and IFNg according to the
manufacturer’s protocol.
Preparation of epidermal sheets for immunohistochemistry
The preparation and the evaluation of epidermal sheets were
described earlier (Baumer et al., 2005). In short, the epidermis was
separated from the dermis by means of ammonium thiocyanate. The
dendritic cells were detected with monoclonal anti-mouse MHC II.
Labeling of the antibodies was visualized by using biotinylated
rabbit anti-rat IgG and coupling the antibodies to a fluorochrom
(carbocyanin 3) by streptavidin–biotin technique. The density of
Langerhans cells was counted under the microscope using a 20-fold
magnification and a calibrated grid. Then, 16 randomly chosen areas
per ear were analyzed. Vehicle, FTY720, S1P, and untreated control
ears were analyzed after sensitization.
Immunohistochemical staining of CD3þ , MHC IIþ , and GR-1þ
cells in mouse ears
Cryostat sections (n¼ 6 each group) of mouse ears (7mm) were cut
24 hours after challenge with TDI. The sections were stained using
the alkaline phosphatase anti-alkaline phosphatase technique
(APAAP). The skin was stained for CD3þ T cells, MHC IIþ cells
and for neutrophils as described earlier (Baumer et al., 2004). After
incubation with the primary antibodies and washing, the slices were
incubated with bridging antibodies (rat anti-mouse immunoglobulin
G, Z494, Dako, Hamburg, Germany) and after washing, with the
APAAP complex (D 488, Dako). Fast Blue (Sigma, Deisenhofen,
Germany) served as a substrate for the alkaline phosphatase.
Sections were counterstained with hemalaun. The cell influx was
evaluated by a semi-quantitative examination (range: 0¼ no stain-
ing—3¼ strong staining intensity) by two experienced persons. The
mean staining intensity of each mouse ear evaluated by the two
persons is presented numerically as a scatter box. As this method is
not quantitative, no statistics were performed.
Statistical evaluation
All experiments were performed in at least two independent settings
with comparable results. Figures are presented as mean (±SD).
Statistically significant differences between the drug treatments and
controls were assessed by a one-way analysis of variance followed
by a post hoc test (Dunnett’s test). When two groups are compared a
Mann–Whitney rank sum test was performed.
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